COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01041235
Recruitment Status : Completed
First Posted : December 31, 2009
Last Update Posted : September 6, 2012
Information provided by (Responsible Party):
Azaya Therapeutics, Inc.

Brief Summary:
The purpose of this study is to determine the safety profile, including the maximum tolerated dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Breast Cancer Ovarian Cancer Pancreatic Cancer Non-Small Cell Lung Drug: ATI-1123 (active drug = docetaxel) Phase 1

Detailed Description:

The majority of advanced stage human cancers are fatal if not treated promptly and aggressively. Standard treatments include chemotherapy, radiation therapy and surgery. Docetaxel, the active ingredient in ATI-1123 and the FDA approved drug Taxotere, is a chemotherapy given by IV to patients to treat various types of cancers.

Docetaxel is a poorly water soluble semi-synthetic taxane analog commonly used in the treatment of a variety of solid tumors including non-small cell lung, prostate, breast, gastric and head and neck cancer. Because of its poor water solubility it is formulated with co-solvents that can potentially contribute to treatment related adverse events such as hypersensitivity. Current taxane formulations often complicate drug delivery and can alter both pharmacokinetic and toxicity profiles.

Results from nonclinical evaluations show that ATI-1123 retains the antineoplastic activity of docetaxel while removing the need for unwanted solvents like Tween 80. The administration of ATI-1123 versus other docetaxel chemotherapy formulations is expected to reduce hypersensitivity reactions (redness, swelling, itching at the infusion site), eliminate the requirement for premedications, have a broader therapeutic index, and enhance systemic docetaxel exposure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors
Study Start Date : December 2009
Actual Primary Completion Date : October 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: ATI-1123 Drug: ATI-1123 (active drug = docetaxel)
Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
Other Names:
  • ATI-1123
  • ATI1123
  • Docetaxel
  • Docetaxol
  • Taxotere

Primary Outcome Measures :
  1. To determine the (MTD) and (DLTs) of ATI-1123 administered every 3 weeks, over a range of doses in patients with advanced solid tumors. [ Time Frame: Duration of study ]
  2. To establish the dose recommended for future phase II studies with ATI-1123. [ Time Frame: End of Study ]

Secondary Outcome Measures :
  1. To establish the pharmacokinetics of intravenously administered ATI-1123. [ Time Frame: Cycle 1 (various time points within the cycle) ]
  2. To observe patients for any evidence of antitumor activity of ATI-1123 by objective radiographic assessment. [ Time Frame: Every 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Understand and sign a written IRB-approved informed consent form.
  • Have a histologically confirmed solid tumor.
  • Have progressive disease following standard/approved chemotherapy or have no appropriate alternative therapy available.
  • Have one or more tumors measurable or evaluable as outlined by modified RECIST or evaluable by CT or MRI scan.
  • Have an ECOG performance status of ≤ 2.
  • Have a life expectancy of at least 3 months.
  • Be ≥ 18 years old.
  • Have a negative pregnancy test (if female of childbearing potential)
  • Demonstrate acceptable hepatic function:
  • Bilirubin ≤ upper limit of normal (ULN)
  • AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN
  • Demonstrate acceptable renal function:
  • Serum creatinine ≤ 1.5 x ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal (Calculated according to the Cockroft and Gault formula)
  • Demonstrate acceptable hematologic status:
  • Absolute neutrophil count ≥ 1500/mm3
  • Platelet count ≥ 100,000/mm3 (measured within 72 hours prior to initial dose)
  • Hemoglobin ≥ 9 g/dL
  • Demonstrate acceptable coagulation status:
  • PT or INR within 1.5x ULN
  • PTT within 1.5x ULN
  • Have recovered from prior treatments (eg, surgery, radiation, chemotherapy, investigational therapies) sufficiently prior to Day 1 so that, in the opinion of the Investigator and/or Medical Monitor, the protocol objectives would not be compromised.
  • Agree to use an effective contraceptive method (hormonal or barrier method; or abstinence) for the duration of the study and for 30 days after the last dose (for men and women of child-producing potential).

Exclusion Criteria:

  • Have New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Day 1, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG).
  • Have a seizure disorder requiring anticonvulsant therapy.
  • Have active CNS metastasis. Patients with a history of CNS metastases will be eligible if they have been treated and are stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on stable dose of steroids for ≥ 1 week prior to enrollment.
  • Have severe, chronic obstructive pulmonary disease with hypoxemia.
  • Have active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
  • Are pregnant or nursing.
  • Have undergone radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry (6 weeks for nitrosoureas or Mitomycin C).
  • Are unwilling or unable to comply with procedures required in this protocol.
  • Have a known history of infection with HIV, hepatitis B, or hepatitis C.
  • Have a serious nonmalignant disease that, in the opinion of the Investigator and/or the Medical Monitor, could compromise protocol objectives.
  • Are currently receiving any other investigational agent.
  • Have exhibited allergic reactions to docetaxel, or a similar structural compound, biological agent, or formulation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01041235

Layout table for location information
United States, Texas
Mary Crowley Cancer Research Centers (MCCRC)
Dallas, Texas, United States, 75230
Cancer Therapy and Research Center (CTRC)
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Azaya Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Anthony W Tolcher, MD South Texas Accelerated Research Therapeutics (START)
Principal Investigator: John Nemunaitis, MD Mary Crowley Cancer Research Center
Study Chair: Jon M Rogers, MD Azaya Therapeutics, Inc (Medical Monitor)
Additional Information:
Layout table for additonal information
Responsible Party: Azaya Therapeutics, Inc. Identifier: NCT01041235    
Other Study ID Numbers: ATI1123-101
First Posted: December 31, 2009    Key Record Dates
Last Update Posted: September 6, 2012
Last Verified: September 2012
Keywords provided by Azaya Therapeutics, Inc.:
Solid Neoplasms
Non Small Cell Lung
Head and Neck
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action